Biomerica (NDSQ:BMRA) announced that it received CE Mark and is launching a high-volume production version of its COVID-19 rapid test.
Irvine, Calif.-based Biomerica’s IgG/IgM rapid test uses the finger-prick method to test blood with results obtained within 10 minutes. The test can be performed by trained professionals anywhere.
The company’s new high-volume version of the disposable serology test offers a way to ramp up production with a proprietary card system that eliminates most plastic, according to a news release. The new version is intended for larger customers performing high-volume screenings.
Biomerica also announced that it is shipping the previously announced cassette version of the finger prick test to distribution partners that are supplying multiple customers, such as NATO, government agencies in Germany, Switzerland, the Netherlands and more.
“The devastating effects on the lives of people affected by COVID-19 continues to be problematic,” Biomerica chairman & CEO Zackary Irani said in the release. “Our existing point of care test has been well accepted in international markets and we are now expanding sales distribution to other countries.
Our launch of these COVID-19 serology tests is by no means a shift in the Company’s stated strategy of growing both our colorectal disease detection product, finalizing clinical trials and gaining FDA approval for our HP Detect H. Pylori test and our InFoods IBS therapy product.”
